Solara Active Pharma Sciences Limited
NSE:SOLARA.NS
742.9 (INR) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | 2019 Q2 | 2019 Q1 | 2018 Q4 | 2018 Q3 | 2018 Q2 | 2018 Q1 | 2017 Q4 | 2017 Q2 | 2017 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 3,634.9 | 2,626.4 | 2,487.3 | 4,252.4 | 3,523.1 | 3,806.2 | 3,947.5 | 3,383.7 | 3,300.7 | 3,230.3 | 1,003.4 | 4,016.1 | 4,055.7 | 4,030.6 | 4,266.9 | 3,975.6 | 3,484.2 | 2,426.6 | 3,436.8 | 3,511.3 | 3,301.7 | 3,207.13 | 3,562.3 | 3,423.3 | 3,028.1 | 3,042 | 398.18 | 2,585.22 |
| Cost of Revenue
| 2,816.6 | 1,599.8 | 3,041.2 | 2,375.3 | 1,919.9 | 1,924.3 | 2,113.9 | 1,893.9 | 1,956.1 | 2,780.6 | 541.6 | 1,871.1 | 1,784.6 | 2,580.5 | 1,876.9 | 1,741.6 | 1,496.8 | 1,712 | 1,482 | 1,696.2 | 1,517.1 | 2,433.33 | 1,755.5 | 1,760.6 | 1,518.4 | 1,550 | 241.47 | 1,311.17 |
| Gross Profit
| 818.3 | 1,026.6 | -553.9 | 1,877.1 | 1,603.2 | 1,881.9 | 1,833.6 | 1,489.8 | 1,344.6 | 449.7 | 461.8 | 2,145 | 2,271.1 | 1,450.1 | 2,390 | 2,234 | 1,987.4 | 714.6 | 1,954.8 | 1,815.1 | 1,784.6 | 773.8 | 1,806.8 | 1,662.7 | 1,509.7 | 1,492 | 156.71 | 1,274.05 |
| Gross Profit Ratio
| 0.225 | 0.391 | -0.223 | 0.441 | 0.455 | 0.494 | 0.464 | 0.44 | 0.407 | 0.139 | 0.46 | 0.534 | 0.56 | 0.36 | 0.56 | 0.562 | 0.57 | 0.294 | 0.569 | 0.517 | 0.541 | 0.241 | 0.507 | 0.486 | 0.499 | 0.49 | 0.394 | 0.493 |
| Reseach & Development Expenses
| 0 | 1,010 | 108 | 110 | 100 | 103 | 95 | 95 | 80 | 119 | 135 | 143 | 141 | 140.1 | 138 | 111 | 0 | 225.7 | 134 | 110 | 0 | 229.3 | 104 | 111 | 0 | 27 | 0 | 0 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 680.7 | 0 | 0 | 0 | 571.2 | 0 | 0 | 0 | 609.1 | 0 | 0 | 0 | 557.3 | 0 | 0 | 0 | 528.5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 8.6 | 0 | 0 | 0 | 3.8 | 0 | 0 | 0 | 3.1 | 0 | 0 | 0 | 15.6 | 0 | 0 | 0 | 22.8 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 649.8 | 736.8 | 1,214.6 | 749.6 | 611.5 | 689.3 | 704.1 | 557.6 | 600.7 | 575 | 640 | 624 | 604.4 | 612.2 | 598.8 | 580.1 | 545 | 572.9 | 514.3 | 506.3 | 486.3 | 551.3 | 487.4 | 460.5 | 427.5 | 1,035 | 0 | 0 |
| Other Expenses
| 5.6 | 17 | -1,318.1 | 11.8 | 20.4 | 46.8 | 71.7 | 37.2 | 69.8 | -63.2 | 47.3 | 33.1 | 59.1 | -105.3 | 82.9 | 61.2 | 45.8 | -46 | 60.8 | 49.5 | 43.6 | 17.07 | 38.8 | 13.9 | 4.8 | 0 | -19.71 | 22.61 |
| Operating Expenses
| 649.8 | 1,181.5 | 1,322.6 | 1,762.9 | 1,671.1 | 1,658.7 | 1,663.4 | 1,500.4 | 1,500.4 | 441.8 | 1,714.6 | 1,710.2 | 1,633.7 | 701.3 | 1,610.5 | 1,533.8 | 1,411.7 | 407.2 | 1,416.6 | 1,369.9 | 1,376.7 | 229.22 | 1,399.2 | 1,375.4 | 1,239.8 | 1,285 | 73.38 | 1,070.96 |
| Operating Income
| 168.5 | -137.9 | -1,876.5 | 126 | -67.9 | 270 | 241.9 | 26.6 | -155.8 | -142.9 | -1,252.8 | 434.8 | 637.4 | 748.8 | 779.5 | 700.2 | 575.7 | 307.4 | 538.2 | 445.2 | 407.9 | 544.58 | 407.6 | 287.3 | 269.9 | 254 | 83.33 | 203.09 |
| Operating Income Ratio
| 0.046 | -0.053 | -0.754 | 0.03 | -0.019 | 0.071 | 0.061 | 0.008 | -0.047 | -0.044 | -1.249 | 0.108 | 0.157 | 0.186 | 0.183 | 0.176 | 0.165 | 0.127 | 0.157 | 0.127 | 0.124 | 0.17 | 0.114 | 0.084 | 0.089 | 0.083 | 0.209 | 0.079 |
| Total Other Income Expenses Net
| -303.1 | -1,528.7 | -876.9 | -296.6 | -225.7 | -219.6 | -236.4 | -219.6 | -155.2 | -167.1 | -146.1 | -138 | -136.3 | -182.6 | -121.6 | -132.5 | -152.5 | -128.4 | -124.9 | -153.4 | -142.9 | -283.05 | -186.6 | -185.5 | -177.4 | -170 | 122.64 | -15.72 |
| Income Before Tax
| -134.6 | -1,666.6 | -2,753.4 | -170.6 | -293.6 | 50.4 | 5.5 | -193 | -311 | -310 | -1,398.9 | 296.8 | 501.1 | 566.2 | 657.9 | 567.7 | 423.2 | 179 | 413.3 | 291.8 | 265 | 261.53 | 221 | 101.8 | 92.5 | 84 | 205.97 | 187.37 |
| Income Before Tax Ratio
| -0.037 | -0.635 | -1.107 | -0.04 | -0.083 | 0.013 | 0.001 | -0.057 | -0.094 | -0.096 | -1.394 | 0.074 | 0.124 | 0.14 | 0.154 | 0.143 | 0.121 | 0.074 | 0.12 | 0.083 | 0.08 | 0.082 | 0.062 | 0.03 | 0.031 | 0.028 | 0.517 | 0.072 |
| Income Tax Expense
| 0 | 887.9 | 259.64 | 1 | -102.5 | 12.8 | -1.2 | -93.2 | -144.5 | -221.9 | 47.1 | 32.8 | 58.9 | 0.1 | 0.1 | 0.8 | 0.5 | 0.9 | 60.5 | 3 | 43.4 | -0.4 | 38.9 | 6.3 | 71.7 | 21 | 3.77 | 29.2 |
| Net Income
| -134.6 | -2,553.4 | -2,753.4 | -171.6 | -195.5 | 37.6 | 4.5 | -99.6 | -164.3 | 18.8 | -1,398.7 | 297.1 | 501.3 | 566.5 | 658 | 566.7 | 422.8 | 178.2 | 413.6 | 289.1 | 265.2 | 263.27 | 220.9 | 85.3 | 25.6 | 63 | 202.04 | 158.26 |
| Net Income Ratio
| -0.037 | -0.972 | -1.107 | -0.04 | -0.055 | 0.01 | 0.001 | -0.029 | -0.05 | 0.006 | -1.394 | 0.074 | 0.124 | 0.141 | 0.154 | 0.143 | 0.121 | 0.073 | 0.12 | 0.082 | 0.08 | 0.082 | 0.062 | 0.025 | 0.008 | 0.021 | 0.507 | 0.061 |
| EPS
| -3.5 | -65.37 | -76.49 | -4.77 | -5.43 | 1.05 | 0.13 | -2.77 | -4.57 | 0.53 | -38.93 | 8.27 | 13.95 | 15.9 | 18.47 | 19.21 | 15.75 | 6.04 | 16 | 11.21 | 10.29 | 8.92 | 8.96 | 3.46 | 0.23 | 2.55 | 6.85 | 14.13 |
| EPS Diluted
| -3.5 | -65.37 | -76.49 | -4.77 | -5.43 | 1.05 | 0.13 | -2.77 | -4.56 | 0.52 | -38.93 | 8.22 | 13.88 | 15.9 | 17.29 | 17.25 | 14.74 | 6.04 | 15.24 | 11.16 | 10.22 | 8.92 | 8.95 | 3.46 | 0.23 | 2.55 | 6.85 | 14.13 |
| EBITDA
| 419.2 | 114.6 | -1,616.9 | 388.1 | 211.6 | 534.5 | 521.7 | 312.9 | 195.3 | 242.2 | -921.1 | 751.7 | 973.3 | 1,046.5 | 1,136.3 | 1,037.4 | 883.8 | 519.7 | 837.4 | 729.7 | 680.4 | 619.45 | 658.5 | 494.9 | 465.8 | 333.18 | 88.48 | 364.98 |
| EBITDA Ratio
| 0.115 | 0.044 | -0.65 | 0.091 | 0.06 | 0.14 | 0.132 | 0.092 | 0.059 | 0.075 | -0.918 | 0.187 | 0.24 | 0.26 | 0.266 | 0.261 | 0.254 | 0.214 | 0.244 | 0.208 | 0.206 | 0.193 | 0.185 | 0.145 | 0.154 | 0.11 | 0.222 | 0.141 |